What is OneThree Biotech?
OneThree Biotech is a clinically validated, biology-driven artificial intelligence (AI) company. It leverages a proprietary AI platform combined with systems biology to decipher the intricate mechanisms driving drug-target-disease relationships. The company's technology integrates diverse datasets—chemical, biological, and clinical—with advanced computational tools to address complex challenges in disease biology and drug discovery. OneThree Biotech's AI platform has demonstrated efficacy in accelerating early-stage drug discovery and development by rapidly generating novel, actionable insights and hypotheses. This platform's capabilities have been validated through numerous partnerships, clinical trials, and over 20 peer-reviewed publications, solidifying its role in optimizing the drug development pipeline.
How much funding has OneThree Biotech raised?
OneThree Biotech has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2020): $2.5M with participation from Primary Venture Partners and Meridian Street Capital
Key Investors in OneThree Biotech
Primary Venture Partners
Primary Venture Partners is a venture capital firm that likely focuses on early-stage technology investments, potentially including biotech and AI sectors, given their domain.
Meridian Street Capital
Meridian Street Capital is an investment fund that partners with entrepreneurs to grow and develop businesses, suggesting a flexible investment mandate that could encompass innovative biotech ventures.
What's next for OneThree Biotech?
The substantial enterprise-level funding positions OneThree Biotech for significant scaling and further development of its AI-driven drug discovery capabilities. This strategic investment is likely to fuel expansion into new therapeutic areas, enhance its platform's predictive power, and potentially support the progression of its pipeline candidates through later-stage clinical trials. The company's focus on integrating biology with AI suggests a trajectory aimed at disrupting traditional pharmaceutical R&D models, with future growth potentially involving strategic collaborations or acquisitions by larger entities seeking to leverage its innovative technology.
See full OneThree Biotech company page
